Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer

Archives of Dermatology

Volumn 147, Issue 12, 2011, Pages 1395-1402

  Yang, Geoffrey B ^a   Barnholtz Sloan, Jill S ^a   Chen, Yanwen ^a   Bordeaux, Jeremy S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; EYE CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MELANOMA; NONEPITHELIAL SKIN CANCER; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SKIN CANCER; THYROID CANCER;

ADULT; AGE FACTORS; AGED; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; SEER PROGRAM; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84255193053     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.1133     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
3. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999;340(17):1341-1348. (Pubitemid 29196597)
4. Olsen CM, Zens MS, Stukel TA, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer. 2009; 124(4):937-944.
5. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996; 61(2):274-278. (Pubitemid 26044543)
6. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA. 1997;277(18):1439- 1444. (Pubitemid 27208885)
7. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95(11):806-812. (Pubitemid 36798427)
8. Rivers JK. Melanoma. Lancet. 1996;347(9004):803-806. (Pubitemid 26091646)
9. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316.
10. Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer. 2004;111(5):792-794. (Pubitemid 39062905)
11. Goldstein AM, Chan M, Harland M, et al. Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006; 66(20):9818-9828. (Pubitemid 44672032)
12. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995; 333(15):970-974.
13. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotypephenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000;92(12):1006-1010. (Pubitemid 30469967)
14. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: the xeroderma pigmentosum paradigm. Arch Dermatol. 1994;130(8):1018-1021. (Pubitemid 24255035)
15. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12(1):97-99. (Pubitemid 26013159)
16. Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma: screening implications. Cancer. 1995;75(2)(suppl):707-714.
17. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146(3): 265-272.
18. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001;145(6):981-985. (Pubitemid 34204474)
19. Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol. 2010;62(5):757-767.
20. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996;73(2):255-259. (Pubitemid 26028343)
21. Cantwell MM, Murray LJ, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer. 2009; 100(1):174-177.
22. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database. Version 6.6.2. Bethesda, MD: National Cancer Institute. http://www.seer.cancer .gov/. Accessed February 20, 2011.
23. Fritz AG. International Classification of Diseases for Oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
24. McCann J. Gender differences in cancer that don't make sense-or do they? J Natl Cancer Inst. 2000;92(19):1560-1561, 1562.
25. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995;33(6):923-936.
26. Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: twoyear results from a population-based study. Arch Dermatol. 2006;142(4):433- 438.
27. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet. 1978;15(5):352-356. (Pubitemid 9041252)
28. Oram SW, Liu XX, Lee TL, Chan WY, Lau YF. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer. 2006;6:154.
29. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ. 1995;310(6993): 1491-1495.
30. Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 1995;87(10):732-741.
31. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935-4944.
32. Hurst EA, Harbour JW, Cornelius LA. Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol. 2003;139(8):1067-1073. (Pubitemid 36994834)
33. Shors AR, Iwamoto S, Doody DR, Weiss NS. Relationship of uveal and cutaneous malignant melanoma in persons with multiple primary tumors. Int J Cancer. 2002;102(3):266-268. (Pubitemid 35222296)
34. Faggiano F, Partanen T, Kogevinas M, Boffetta P. Socioeconomic differences in cancer incidence and mortality. IARC Sci Publ. 1997;(138):65-176.
35. Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit. 2005;11(5):RA163-RA172. (Pubitemid 40790954)
36. Mao Y, Hu J, Ugnat AM, Semenciw R, Fincham S; Canadian Cancer Registries Epidemiology Research Group. Socioeconomic status and lung cancer risk in Canada. Int J Epidemiol. 2001;30(4):809-817.
37. Flood A, Peters U, Chatterjee N, Lacey JV Jr, Schairer C, Schatzkin A. Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev. 2005; 14(1):126-132. (Pubitemid 40165292)
38. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxy vitamin D and colon cancer: eight-year prospective study. Lancet. 1989;2(8673):1176-1178. (Pubitemid 19275448)
39. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004; 80(6)(suppl):1678S-1688S.
40. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634. (Pubitemid 32786275)
41. Joosse A, de Vries E, Eckel R, et al. Munich Melanoma Group. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131(3):719-726.
42. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA. 1987;258(21):3125-3130. (Pubitemid 17156228)
43. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL Jr, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008;26(1): 66-75.
44. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007; 109(1):100-108. (Pubitemid 46120199)
45. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol. 2002;138(5):609-614.
46. Cockburn M, Swetter SM, Peng D, Keegan TH, Deapen D, Clarke CA. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol. 2008;59(6):1081-1085.